Detalles de la búsqueda
1.
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab
; 24(9): 1840-1849, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35589610
2.
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab
; 24(7): 1360-1369, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403793
3.
Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Diabetes Obes Metab
; 20(12): 2885-2893, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30259644
4.
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Diabetes Obes Metab
; 20(5): 1148-1155, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29316130
5.
Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.
Front Endocrinol (Lausanne)
; 14: 1175640, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37409229
6.
Improving HbA1c Control in Type 1 or Type 2 Diabetes Using Flash Glucose Monitoring: A Retrospective Observational Analysis in Two German Centres.
Diabetes Ther
; 12(1): 363-372, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33314006
7.
A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
Diabetes Care
; 43(8): 1710-1716, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32209647
8.
Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials.
Diabetes Ther
; 10(3): 1029-1041, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30949906
9.
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
Diabetes Care
; 41(9): 1926-1937, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30026333
10.
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
J Clin Endocrinol Metab
; 103(6): 2291-2301, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29688502
11.
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Lancet Diabetes Endocrinol
; 5(5): 355-366, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28344112
12.
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
Diabetes Care
; 40(7): 943-950, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28356319
13.
Real-World Data Collection Regarding Titration Algorithms for Insulin Glargine in Patients With Type 2 Diabetes Mellitus.
J Diabetes Sci Technol
; 10(5): 1122-9, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27325389
14.
No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study.
J Diabetes Sci Technol
; 6(6): 1392-7, 2012 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23294785
Resultados
1 -
14
de 14
1
Próxima >
>>